Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643–1647 (1991). • Provided a existence of tumor-specific antigen recognized by cytotoxic T lymphocytes and showed the possibility of targeted immunotherapies.
  Medline CASGoogle Scholar
• 2 Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909–915 (2004).
  Medline CASGoogle Scholar
• 3 Itoh K, Yamada A, Mine T, Noguchi M. Recent advances in cancer vaccines: an overview. Jpn. J. Clin. Oncol. 39(2), 73–80 (2009).
  MedlineGoogle Scholar
• 4 Mine T, Sato Y, Noguchi M et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin. Cancer Res. 10(3), 929–937 (2004). • Reported that peptide-specific immunoglobulin could be a biomarker to predict prolonged survival after peptide vaccinations.
  Medline CASGoogle Scholar
• 5 Rosato A, Zoso A, Dalla Santa S et al. Predicting tumor outcome following cancer vaccination by monitoring quantitative and qualitative CD8+ T cell parameters. J. Immunol. 176(3), 1999–2006 (2006).
  Medline CASGoogle Scholar
• 6 Yutani S, Komatsu N, Yoshitomi M et al. A Phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. Oncol. Rep. 30(3), 1094–1100 (2013).
  Medline CASGoogle Scholar
• 7 Corbiere V, Chapiro J, Stroobant V et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer. Res. 71(4), 1253–1262 (2011). • Suggested that antigen spreading (a new cytotoxic T-lymphocyte clone against previously ignored antigens) is occurring in regressing metastases after vaccination.
  Medline CASGoogle Scholar
• 8 Kyogoku N, Ikeda H, Tsuchikawa T et al. Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan (CHP)-MAGE-A4. Oncol. Lett. (2016) (In press).
  MedlineGoogle Scholar
• 9 Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188, 22–32 (2002).
  Medline CASGoogle Scholar
• 10 De Plaen E, Naerhuyzen B, De Smet C, Szikora JP, Boon T. Alternative promoters of gene MAGE4a. Genomics 40(2), 305–313 (1997).
  Medline CASGoogle Scholar
• 11 Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC, Resnick MB. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin. Cancer Res. 9(17), 6453–6460 (2003).
  Medline CASGoogle Scholar
• 12 Gure AO, Chua R, Williamson B et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin. Cancer Res. 11(22), 8055–8062 (2005).
  Medline CASGoogle Scholar
• 13 Barrow C, Browning J, MacGregor D et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin. Cancer Res. 12(3 Pt 1), 764–771 (2006).
  Medline CASGoogle Scholar
• 14 Gu XG, Schmitt M, Hiasa A et al. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer. Res. 58(15), 3385–3390 (1998).
  Medline CASGoogle Scholar
• 15 JCOG (Japan Clinical Oncology Group). Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines. Int. J. Clin. Oncol. 9(Suppl. 3), 1–82 (2004).
  Google Scholar
• 16 Saito T, Wada H, Yamasaki M et al. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine 32(45), 5901–5907 (2014).
  Medline CASGoogle Scholar
• 17 Karbach J, Neumann A, Atmaca A et al. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin. Cancer Res. 17(4), 861–870 (2011).
  Medline CASGoogle Scholar
• 18 Mizukoshi E, Yamashita T, Arai K et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 57(4), 1448–1457 (2013).
  Medline CASGoogle Scholar
• 19 Kawabata R, Wada H, Isobe M et al. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int. J. Cancer 120(10), 2178–2184 (2007).
  Medline CASGoogle Scholar
• 20 Jager E, Gnjatic S, Nagata Y et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl Acad. Sci. USA 97(22), 12198–12203 (2000).
  Medline CASGoogle Scholar
• 21 Kawada J, Wada H, Isobe M et al. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. Int. J. Cancer 130(3), 584–592 (2012). •Immunoglobulin titers against nontargeted cancer-testis antigens were elevated after NY-ESO-1 protein vaccination.
  Medline CASGoogle Scholar
• 22 Noguchi T, Kato T, Wang L et al. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res. 72(7), 1672–1682 (2012). •• Suggested that antitumor effects of humoral response were strengthened by the combination of anticancer drugs.
  Medline CASGoogle Scholar
• 23 Gupta A, Nuber N, Esslinger C et al. A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. Cancer Immun. 13, P3 (2013).
  MedlineGoogle Scholar
• 24 Matsueda S, Komatsu N, Kusumoto K et al. Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases. Dev. Comp. Immunol. 41(1), 68–76 (2013).
  Medline CASGoogle Scholar
• 25 Kageyama S, Wada H, Muro K et al. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J. Transl. Med. 11, 246 (2013).
  MedlineGoogle Scholar